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Abstract
Background: Researchers report difficulties in conducting research with children and young people with life-limiting conditions or 
life-threatening illnesses and their families. Recruitment is challenged by barriers including ethical, logistical and clinical considerations.
Aim: To explore how children and young people (aged 0–25 years) with life-limiting conditions or life-threatening illnesses and their 
families were identified, invited and consented to research published in the last 5 years.
Design: Systematic review.
Data sources: MEDLINE, PsycINFO, Web of Science, Sciences Citation Index and SCOPUS were searched for original English 
language research published between 2009 and 2014, recruiting children and young people with life-limiting conditions or life-
threatening illness and their families.
Results: A total of 215 studies – 152 qualitative, 54 quantitative and 9 mixed methods – were included. Limited recruitment 
information but a range of strategies and difficulties were provided. The proportion of eligible participants from those screened could 
not be calculated in 80% of studies. Recruitment rates could not be calculated in 77%. A total of 31% of studies recruited less than 50% 
of eligible participants. Reasons given for non-invitation included missing clinical or contact data, or clinician judgements of participant 
unsuitability. Reasons for non-participation included lack of interest and participants’ perceptions of potential burdens.
Conclusion: All stages of recruitment were under reported. Transparency in reporting of participant identification, invitation and 
consent is needed to enable researchers to understand research implications, bias risk and to whom results apply. Research is needed 
to explore why consenting participants decide to take part or not and their experiences of research recruitment.
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Review Article
What is already known about this topic?
•• Recruitment to research with children and young people with life-limiting conditions or life-limiting illnesses is challenged 
by factors including limited researcher access to participants, ethical considerations and characteristics of the population.
What this paper adds?
•• Recruitment strategies are not consistently reported in current research with this population.
•• Inadequate reporting of recruitment practices limits our capacity to judge study quality, risk of bias, representativeness 
of samples, generalizability of results and ultimately the applicability of findings.
 at University College London on September 12, 2016pmj.sagepub.comDownloaded from 
2 Palliative Medicine 
Introduction
There is an international need for research of all types 
involving children and young people aged 0–25 years 
(CYP) with life-limiting conditions (LLC; conditions for 
which there is no reasonable hope of cure and from which 
children or young people will die1) or life-threatening ill-
nesses (LTI; conditions for which curative treatment may 
be feasible but can fail2) and their families.3 Research is 
required to explore pain and symptom management, deci-
sion making about care and treatment, illness experience, 
and service development and delivery.
A number of challenges to recruitment for research with 
this group have been reported in the literature.4 These 
include clinical considerations such as the often unpredict-
able course of the illnesses,5 limited access to potential 
participants as a result of both logistical factors and pater-
nalistic attitudes,6 the perceived potential burden on par-
ticipants7 and difficulties securing ethical approval.8 As a 
result, recruitment to research may be slow and selective.7 
This may affect the quality of research, risk of bias and the 
generalizability of findings.9,10
There is debate about when and how, and even if, CYP 
with LLC/LTI and their families might be invited to take 
part in research.11 At the same time, there is also growing 
evidence that CYP with LLC/LTI and their families value 
opportunities to participate in research and that this can be 
a positive experience for them.11–13
Internationally, the culture of research is changing14,15 
as the importance of establishing robust evidence for care 
is increasingly understood. In the United Kingdom, the 
National Institute for Health Research (NIHR) has estab-
lished a Clinical Research Network for Children, and CYP 
and their families are being encouraged to share their 
views and participate in the design, review and conduct of 
research to ensure that it is valid, feasible and acceptable to 
potential participants.16–19
CYP with LLC/LTI are likely to receive a palliative 
approach to care, often alongside active treatments.20 
Interest in research on both adult and children’s pallia-
tive care is gaining momentum and guidance has been 
developed for its design and conduct. The MORECare 
(Methods of Researching End of Life Care) statement21 
provides best practice solutions specifically for plan-
ning and conducting palliative care research, as well as 
the reporting of attrition data. However, it appears that 
such guidance is not routinely adhered to and a lack of 
reporting of methodological information has been iden-
tified in research with CYP with LLC/LTI and their 
families.14–16,22
In this systematic review, we explored the reported 
methods of participant identification, invitation and 
recruitment of CYP with LLC/LTI and their families to 
research, conducted internationally and published over the 
last 5 years (September 2009 to September 2014). We 
wished to understand the challenges to recruitment, how 
these differ between types of studies, identify areas of 
good practice and provide evidence for areas in which 
improvements might be made.
Aims and objectives
We aimed to explore methods of recruitment of CYP with 
LLC/LTI and their families to qualitative, quantitative and 
mixed-methods research reported in peer-reviewed journal 
articles.
Our objectives were as follows:
1. To document the procedures for identifying, invit-
ing and consenting eligible CYP with LLC/LTI and 
their families to research;
2. To document recruitment rates;
3. To identify reasons given for non-enrolment, both 
reasons given by researchers and clinicians for not 
approaching eligible participants, and those given by 
potential participants for deciding not to take part;
4. To explore whether recruitment differs between 
types of studies;
5. To explore what barriers and facilitators to research 
recruitment were highlighted by the authors of 
reviewed studies.
Methods
Inclusion criteria
Primary studies of all methodologies (quantitative, quali-
tative and mixed-method design) were included. Eligible 
studies reported research recruiting CYP with LLC/LTI 
(and/or their family members), were written in English and 
•• Greater and clearer reporting of participant identification, invitation, screening, eligibility and consenting practices is 
needed for research recruiting children and young people (CYP) with life-limiting conditions (LLC)/life-threatening ill-
nesses (LTI) and their families.
Implications for practice, theory or policy
•• Consistent use of reporting guidelines and online supplements should be encouraged by all journals.
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published between September 2009 and September 2014. 
Conference abstracts were not included. We applied the 
United Nations definition of ‘young people’, extending 
from birth to 25 years. Studies recruiting parents, grand-
parents or siblings of CYP with LLC/LTI were also 
included. The Richard Hain Directory23 of International 
Classification of Diseases, 10th Revision (ICD-10) diag-
noses was used to ascertain whether diagnoses could be 
considered life-limiting or life-threatening; where defini-
tions were unclear, the opinion of a clinical expert in pae-
diatric palliative care (M.C.) was sought.
Search strategy
A systematic search of the literature was performed in the 
following: MEDLINE, PsycINFO, Web of Science, 
Sciences Citation Index and SCOPUS in September 2014. 
A combination of indexed and free-text terms was used to 
reflect the three components forming the search strategy 
(CYP; LLC/LTI recruitment).
Descriptive terms that have been used previously by 
other systematic reviews24,25 relating to all stages of youth 
were used. Terms relating to palliative care, death, bereave-
ment and recruitment practices were also included. The 
MEDLINE search strategy is shown in Appendix 1.
Data screening
Two reviewers (B.F.H. and L.J.M.O.) screened citations 
against the inclusion criteria. Disagreements regarding eli-
gibility were resolved through reading full text articles and 
discussion.
Data extraction
The data extraction tool was piloted by B.F.H. and L.J.M.O., 
and minor adjustments were made. We sought to extract the 
following from each study: research design, recruitment 
location and setting, funding source and type of body pro-
viding ethical review, sample characteristics, and numbers 
of participants screened, identified as eligible, invited to 
participate and consented. We also extracted reasons for the 
non-invitation of eligible participants and reasons given by 
eligible participants for non-participation. Data were 
extracted independently by one of four reviewers (B.F.H., 
L.J.M.O., V.V. or B.C.). A sample of data extracted by each 
reviewer was checked for accuracy and consistency by 
another reviewer.
Where data that we wished to extract could not be found 
in the article, we categorized this as ‘not reported’. No 
attempts were made to obtain this information by contacting 
the authors. We did not assess, alongside data extraction, the 
overall quality of each study using recommended checklists 
as we wished to explore the quality of reporting of recruit-
ment information, rather than quality of the research itself.
If provided, descriptions of researchers’ experiences of 
recruiting participants were also extracted. We were inter-
ested in strategies employed by authors that aimed to facili-
tate recruitment and any issues encountered which hindered 
the recruitment processes. This information was usually 
found in the discussion section of the included papers. 
These data were not available in all reviewed studies.
Data analysis
Quantitative analysis
We used descriptive statistics to summarize the type of 
studies included, the recruitment strategies employed and 
the recruitment rates achieved. If we had found sufficient 
levels of reporting of items of interest, we planned to con-
duct comparative statistical analyses to assess differences 
in recruitment rates between (1) studies with different 
types of aims, such as intervention studies and psychoso-
cial studies and (2) studies using different participant invi-
tation methods, for example, an invitation letter in 
comparison to inviting participants in person.
Qualitative analysis
Any text specifically on researchers’ experiences of recruit-
ing their sample was identified and analysed. We applied 
thematic synthesis as outlined by Thomas and Harden26 and 
described in Langford et al.27 to these informal data. 
Thematic synthesis is an adaptation of thematic analysis 
and can be used to pool qualitative data across different 
studies. Three stages of the recruitment process were 
used as a coding (grouping) framework: (1) identifying or 
screening participants, (2) inviting or approaching them to 
participate and (3) obtaining consent. Codes relating to the 
barriers and facilitators experienced in relation to each of 
these stages emerged from the data. Coding was completed 
in NVivo 10 by one reviewer (B.F.H.) and reviewed by two 
further reviewers (B.C. and L.J.M.O.), disagreements were 
resolved through discussion.
Results
Literature search
Figure 1 presents a Preferred Reporting items for 
Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram of the inclusion process. Our initial search yielded 
6419 citations, 215 of these met all criteria and were 
included in this review. Appendix 2 lists references for all 
included studies.
Study types
Table 1 summarizes the research aims of reviewed 
studies.
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Context and setting. Nearly half of reviewed studies were 
conducted in North America (46%), a quarter in Europe 
(26%), 10% in Asia, 7% in Australia and New Zealand, 
6% in Africa, 1% in South America and a minority across 
multiple countries (4%). The majority of research was 
conducted within hospitals (83%).
Sample. Over half of studies recruited only CYP (56%), over 
a third recruited only family members (35%) and the remain-
ing 11% recruited both CYP and family members. Young 
people aged 12–25 years were the least represented with 7% 
of studies recruiting this age group exclusively. The ages of 
CYP were not reported in a consistent manner, making 
descriptions of the ages of participants difficult. Ages of 
CYP with LLC/LTI were reported in 76% of all studies. 
Mean ages reported ranged from 19 min of life to 21.1 years.
CYP with malignant and non-malignant conditions 
were roughly equally represented (malignant: 45%; non-
malignant: 44%; and both conditions: 11%). The majority 
of studies recruited families whose child was alive at the 
Figure 1. PRISMA flow diagram.
Table 1. Research aims of reviewed studies.
Research aim Number of studies (%) Definition
Evaluating an intervention 71 (33) Studies aiming to test the efficacy or safety of a treatment, medical 
intervention (n = 59) or non-medical intervention (n = 12), including 
randomized and non-randomized trials
Assessing quality of life 22 (10) Assessments of quality of life of CYP with LLC/LTI and/or their family 
members
Observing the course of illness 36 (17) Studies monitoring the course of an illness without providing additional 
interventions other than standard care
Exploring views and 
perspectives
60 (28) Qualitative studies exploring experiences, views or perspectives of CYP 
with LLC/LTI and/or their family members
Evaluating current practice 26 (12) Evaluations of current non-medical practice or research-related practice, 
from the perspective of CYP with LLC/LTI and/or their family members
CYP: children and young people; LLC: life-limiting conditions; LTI: life-threatening illnesses.
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start of the study (79%). In almost half of the 45 studies 
(47%), recruiting bereaved families, recruitment occurred 
more than 1 year after bereavement (Table 2).
Study design. Most studies were quantitative (71%), 25% 
were qualitative, while mixed-methods studies were 
uncommon (4%). Over a quarter of studies (27%) used 
interviews, 27% used experimental methods, 23% used 
questionnaires, 19% recorded physiological measures and 
4% of studies used other methods.
Recruitment strategies – procedures used 
for identifying, inviting and consenting eligible 
patients and their families to research
Information concerning the methods of participant recruit-
ment was not often reported (Table 3).
Identification of potential participants. Over half of the stud-
ies did not report how potential participants were identified 
(64%). In the 78 studies reporting this, nearly one-third 
identified potential participants using medical records 
(29%) and a quarter used clinic attendance (26%).
Less than a quarter of studies reported the person respon-
sible for identifying potential participants (24%). Physicians 
identified potential participants in nearly half of the studies 
providing this information (48%). Studies evaluating an 
intervention or observing the course of an illness were least 
likely to report how potential participants were identified, 
whereas those evaluating current practice were most likely 
to report their methods for participant identification.
Invitation of participants. Over three quarters of studies did 
not report who invited potential participants (76%). In 
research evaluating an intervention, including treatment for 
disease, 96% of studies did not provide this information. In 
studies reporting this, it was most often a researcher (40%) 
or a physician (20%). Across all studies, 68% did not report 
the methods used for participant invitation, over half of 
those reporting this invited participants by letter (54%) and 
around a third invited participants in person (32%).
Consenting of participants. All studies required informed 
consent prior to participation; however, specifically who 
provided consent was not reported in 22% of studies. The 
majority of studies recruiting both CYP and their family 
(that provided this information) obtained CYP consent/
assent in additional to parental consent (78%).
Recruitment rates and completeness of 
reporting
Numbers of potential participants screened and the propor-
tion found to be eligible. The numbers of participants 
Table 2. Summary of characteristics of reviewed studies, n (%).
All studies 
(n = 215)
Evaluating an 
intervention 
(n = 71, 33%)
Assessing 
quality of life 
(n = 22, 10%)
Observing 
course of illness 
(n = 36, 17%)
Exploring views 
or perspectives 
(n = 60, 28%)
Evaluating 
current practice 
(n = 26, 12%)
Sample, n (%)
 CYP only 116 (56) 66 (93) 6 (27) 34 (95) 9 (16) 1 (4)
 Family members only 75 (35) 2 (3) 11 (50) 2 (5) 43 (71) 17 (65)
 Both CYP and family members 24 (11) 3 (4) 5 (23) – 8 (13) 8 (31)
 CYP alive at recruitment 170 (79) 70 (98) 17 (77) 33 (92) 37 (62) 13 (50)
Diagnosis, n (%)
 Malignant 96 (45) 33 (47) 8 (36) 12 (33) 27 (45) 16 (62)
 Non-malignant 95 (44) 38 (53) 9 (41) 23 (64) 23 (38) 2 (8)
  Mixed malignant or non-
malignant
24 (11) – 5 (23) 1 (3) 10 (17) 8 (30)
Design
 Qualitative 54 (25) 2 (3) 3 (14) 1 (3) 41 (68) 7 (27)
 Quantitative 152 (71) 69 (97) 16 (73) 35 (97) 16 (27) 16 (62)
 Mixed methods 9 (4) – 3 (14) – 3 (5) 3 (11)
Methodology, n (%)
 Interviews 57 (27) – 7 (32) 3 (8) 39 (65) 8 (31)
 Questionnaires 49 (23) – 15 (68) 2 (6) 17 (28) 15 (58)
 Physiological measures 40 (19) 10 (14) – 29 (80) – 1 (4)
 Experimental (randomized) 29 (12) 29 (41) – – – –
  Experimental (non-
randomized)
33 (15) 32 (45) – 1 (3) – 1 (4)
 Other 8 (4) – – 1 (3) 4 (7) 1(4)
CYP: children and young people.
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screened for eligibility were not consistently reported; 
over three quarters of studies did not report this (77%) 
(Table 4).
It was not possible to calculate the proportion of eligi-
ble participants out of those screened in 80% of studies. 
Where this proportion could be calculated, 24% found less 
than half of those screened to be eligible and 76% found 
over half of screened to be eligible for participation.
Proportion approached out of those eligible. The proportion 
of eligible participants approached was not reported in 
nearly three quarters of studies (74%). Of the minority of 
studies providing this information (n = 55), all approached 
over 50% and the majority approached between 75% and 
100% of individuals eligible for participation (93%).
Proportion consented out of those approached. The propor-
tion of eligible participants consented out of those 
approached could not be calculated in over half of the 
studies (62%). Of the 82 studies providing this informa-
tion, the majority consented more than half of approached 
participants (84%), while 16% recruited less than half 
those approached.
Recruitment rate (proportion recruited out of those eligible). Just 
over 10% of studies reported recruitment targets; of these, 
71% met their target. Over three quarters (77%) of studies 
did not provide the necessary information to calculate 
recruitment rates. In the 49 studies where this was possible, 
around a third recruited less than 50% of eligible partici-
pants (31%).
Reasons for non-enrolment
A total of 19% of studies approached all eligible partici-
pants. In 7% of studies, all invited participants decided to 
Table 3. Methods used for the identification and invitation of participants and details of who provided consent for participation.
All studies, 
n (%)
Evaluating an 
intervention 
(n = 71, 33%)
Assessing 
quality of life 
(n = 22, 10%)
Observing 
course of illness 
(n = 36, 17%)
Exploring views 
or perspectives 
(n = 60, 28%)
Evaluating 
current practice 
(n = 26, 12%)
Identification of participants – method
 Medical records 25 (12) 5 (7) 2 (9) 5 (14) 9 (15) 4 (15)
 Clinic attendance 20 (9) 2 (3) 2 (9) 3 (8) 10 (17) 3 (12)
 Database/registry 19 (9) 3 (4) 4 (18) 2 (6) 5 (8) 5 (19)
 Participation in previous research 7 (3) – 1 (5) 3 (8) 2 (3) 1 (4)
 Other 7 (3) 2 (2) 1 (5) – 3 (5) 1 (4)
 Not reported 137 (64) 59 (83) 12 (55) 23 (64) 31 (52) 12 (46)
Identification of participants – person
 Physician 26 (12) – 3 (14) 3 (8) 17 (28) 3 (12)
 Researcher 10 (5) 1 (1) 1 (5) 1 (3) 1 (2) 6 (23)
 Nurse 5 (2) – 1 (5) – 3 (5) 1 (4)
 Other 11 (5) 2 (2) 3 (14) – 5 (8) 1 (4)
 Not reported 163 (76) 68 (96) 14 (64) 32 (89) 34 (57) 15(58)
Invitation of participants – method
 Letter 37 (17) – 8 (36) – 20 (33) 9 (35)
 In person 22 (10) 2 (3) 2 (9) 2 (6) 11 (18) 5 (19)
 Email 1 (1) – – – 1 (2) –
 Telephone 2 (1) – – – 2 (4) –
 Other 7 (4) – 1 (5) 1 (3) 3 (5) 2 (8)
 Not reported 146 (68) 69 (97) 11 (50) 33 (92) 23 (38) 10 (39)
Invitation of participants – person
 Researcher 20 (9) 3 (4) 1 (5) 1 (3) 10 (17) 5 (19)
 Physician 10 (5) – – – 7 (12) 3 (12)
 Nurse 8 (4) – 1 (5) – 6 (10) 1 (4)
 Other 12 (6) 2 (2) 2 (9) 1 (3) 5 (8) 2 (8)
 Not reported 165 (77) 66 (93) 18 (82) 34 (94) 32 (53) 15 (58)
Consenting of participants
 Parents only 109 (50) 34 (48) 10 (46) 18 (50) 37 (62) 10 (39)
 CYP only 4 (2) 1 (1) 1 (5) – 2 (3) –
 Parents and CYP 52 (24) 14 (20) 2 (9) 11 (31) 5 (8) 7 (27)
 Parents and siblings 2 (1) – 1 (5) – 1 (2) 1 (4)
 Siblings 2 (1) – – – 1 (2) 1 (4)
 Parents, siblings and CYP 1 (1) – – – 1 (2) –
 Not reported 48 (22) 19 (27) 6 (27) 6 (17) 10 (17) 7 (27)
CYP: children and young people.
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take part. Despite the majority of studies not approaching 
all eligible participants, 66% did not report reasons for this 
and 80% did not report reasons given by potential partici-
pants for deciding not to participate.
Reasons for not approaching eligible participants (non-invita-
tion). Of the 20% of studies reporting reasons for not con-
tacting eligible participants, the most commonly cited 
were missing participant data (either clinical or contact, 
n = 25), judgements from clinicians of participant unsuita-
bility (n = 14), unanticipated death (n = 13) or caregivers 
denying approach (n = 9). Other reasons included logistical 
considerations (e.g. distance participants lived from hospi-
tal, n = 7), researchers’ perception of participant unsuitabil-
ity (n = 2) and communication difficulties (n = 2).
Reasons given by participants for non-enrolment (non-partici-
pation). For studies in which not all eligible participants 
were recruited, 14% reported reasons given by potential 
participants for non-participation. Lack of interest was the 
most commonly reported reason (n = 10), followed by par-
ticipants’ perception of practical (n = 9) and psychological 
burdens associated with research participation (n = 6). Per-
sonal reasons (n = 5), the child’s condition (n = 3), caregiv-
ers’ perceptions that their child needed their attention 
(n = 3) and refusal to consent to medical/surgical protocols 
(n = 1) or to randomization (n = 1) were also reported.
Researchers’ experiences of recruitment
Text regarding researchers’ experiences of recruitment 
were extracted from 58 studies (26%). This was coded the-
matically in relation to stages of participant recruitment.
Identification of potential participants. The unpredictable 
course and nature of illnesses and differing institutional 
policies and practices across research sites were reported 
as barriers to the identification of potentially eligible par-
ticipants in four studies. Strategies used to facilitate the 
identification of eligible participants included widening 
inclusion criteria (e.g. changing the number of years since 
bereavement28) or seeking support from lay steering 
groups (‘The parent advisors had particular interest in 
improving palliative care services and programs and vol-
unteered to assist’29).
Invitation of participants. Perceived barriers to the invita-
tion of potential participants included gatekeeping from 
both professionals (‘staff … often chose not to approach 
families where the child was at the end of life’) and 
parents (‘In most cases the mother received the initial 
telephone call … This evolved as another layer of gate-
keeping’9). Logistical factors such as being unable to con-
tact potential participants were also reported as barriers 
(‘Many young people were not consistently engaging with 
Table 4. Recruitment rates, numbers of participants screened, found to be eligible, approached and consented in all studies.
All studies, 
n (%)
Evaluating an 
intervention 
(n = 71, 33%)
Assessing 
quality of life 
(n = 22, 10%)
Observing 
course of illness 
(n = 36, 17%)
Exploring views 
or perspectives 
(n = 60, 28%)
Evaluating 
current practice 
(n = 26, 12%)
Numbers of potential participants screened
 <50 7 (3) 4 (6) – 1 (3) 1 (2) 1 (4)
 50–100 8 (4) 2 (3) 1 (5) 2 (6) 1 (2) 2 (8)
 101–1000 29 (14) 10 (14) 4 (18) 5 (15) 7 (12) 3 (12)
 >1000 5 (2) 2 (3) – 2 (6) – 1 (4)
 Not reported 166 (77) 53 (75) 17 (77) 26 (72) 51 (85) 19 (73)
Percentage of eligible participants out of those screened
 0–50 10 (5) 5 (7) 1 (5) 2 (6) 1 (2) 2 (8)
 51–100 31 (15) 10 (16) 3 (14) 6 (17) 4 (7) 7 (27)
 Not reported 173 (80) 55 (77) 18 (81) 16 (44) 55 (92) 17 (65)
Proportion approached out of those eligible (%)
 0–50 – – – – – –
 51–100 55 (26) 18 (25) 5 (23) 8 (22) 16 (26) 8 (31)
 Not reported 160 (74) 53 (75) 17 (77) 28 (78) 44 (73) 18 (69)
Proportion consented out of those approached (%)
 0–50 13 (6) 3 (4) 1 (5) – 5 (9) 4 (16)
 51–100 69 (32) 24 (34) 5 (23) 13 (72) 18 (29) 8 (34)
 Not reported 133 (62) 44 (62) 16 (73) 21 (58) 37 (62) 14 (54)
Recruitment rate (percentage recruited out of those eligible)
 0–50 15 (7) 8 (11) 2 (10) 2 (6) 1 (2) 2 (8)
 51–100 34 (16) 12 (17) 4 (18) 7 (19) 6 (10) 5 (19)
 Not reported 166 (77) 51 (72) 16 (73) 27 (75) 53 (88) 19 (73)
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medical services and hence did not have the opportunity to 
be invited to take part in research’).
Strategies used to facilitate invitation and recruitment 
processes included considerations of the method and tim-
ing of invitations (‘6-24 months after bereavement was 
chosen to facilitate recall whilst being sensitive to the 
emotional requirements of parents’), outlining partici-
pants’ options during the invitation period (‘Providing 
opportunities for parents or formal carers to be present 
during meetings was welcomed by both the young people 
and parents/formal carers’30) or providing monetary 
incentives.
Consenting of participants. Barriers to obtaining consent 
included overcoming participants’ attitudes or preconcep-
tions towards research (‘Some parents felt that their son/
daughter would be unable to participate as they were either 
non-verbal or had severe learning disabilities’30), logistical 
factors and CYP characteristics (‘Symptoms such as 
fatigue can keep children in critical condition from partici-
pating in research’31)
Methods found to facilitate the consenting process 
included incorporating a degree of flexibility (‘Rather than 
press for a decision on participation, they [participants] 
were advised they would be contacted after a week or so to 
discuss the study further’32), the attributes of the research 
team (‘Recruitment to the study depended on the appoint-
ment of an appropriately qualified and experienced 
research officer’9) and attitudes of potential participants 
(‘The majority of families treated in other hospitals … 
approached the physician themselves to discuss the possi-
bility of an autopsy for research aims’33).
Discussion
This review explored systematically how CYP with LLC/
LTI and their families have been identified, invited and 
consented to research, internationally, in the last 5 years.
Statement of principle findings
The majority of reviewed studies did not describe the 
methods employed in the identification, invitation or con-
senting of participants or the numbers considered or 
approached at each stage of the recruitment process. The 
lack of reporting observed that the proportion of eligible 
participants recruited (recruitment rates) could not be cal-
culated in over three quarters of studies. This hindered our 
exploration of differences in recruitment practices between 
different types of research and to identify areas of good 
practice.
Where such information was available, we found that 
the documented reasons for non-invitation included miss-
ing clinical or contact data, or clinician judgements of par-
ticipant unsuitability. The documented reasons for eligible 
patients deciding not to take part included lack of interest 
and participants’ perceptions of potential burdens.
The observed lack of reporting practices has implica-
tions for the interpretation and generalizability of the cur-
rent evidence base underpinning the care and treatment of 
CYP with LLC/LTI and their families. Research with this 
population is open to the potential for bias for a number of 
reasons, whether this is due to characteristics of the popu-
lation, the environment in which it is conducted or the dif-
ferent parties involved in their care. Without knowing who 
was considered and ultimately included or excluded from 
research, we cannot be sure that the results obtained are 
valid, generalizable and relevant for the populations that 
we are interested in. Moving forward research needs to be 
reported transparently in order for readers to be able to 
draw their own conclusions about how to use the informa-
tion available.
Relationship with previous research and current 
reporting standards
Clinicians were most often reported to be responsible for 
the identification of potentially eligible participants and 
there is potential for this process to be influenced by clini-
cian gatekeeping. As 80% of reviewed studies did not 
report how many screened participants were identified as 
eligible, we cannot expand further on this based on the 
findings of this review.
Strategies to overcome barriers to the invitation of par-
ticipants reported included obtaining advice from steering 
groups and parent advisory committees. This is in line with 
current guidance advocating for the involvement of 
patients and the public in research design and conduct.16
Guidance and standards are in place for the conduct and 
reporting of research34 including the CONSORT 
(Consolidated Standards of Reporting Trials) statement,35 
the TREND (Transparent Reporting of Evaluations with 
Nonrandomized Designs) guidelines,36 STROBE 
(STrengthening the Reporting of OBservational studies in 
Epidemiology) guidelines37 and for research with pallia-
tive populations, the MORECare Statement.21,38
While the CONSORT statement asks authors to provide 
information about the numbers of participants screened, 
identified as eligible and to provide reasons for excluding 
participants, not all journals require authors to follow report-
ing guidelines. Indeed information required by the 
CONSORT is not consistently reported in paediatric rand-
omized controlled trials.39,40 This lack of adherence to 
guidelines could go some way to explaining the inconsisten-
cies and inadequacies of reporting evidenced in this review.
The impact of inadequate reporting in research
Much research conducted with CYP with LLC/LTI and 
their families acknowledges its limited generalizability, 
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but fails to report precisely to whom the research is gener-
alizable to. Without the provision of more transparent 
information about the recruitment of CYP with LLC/LTI, 
it will be difficult to develop a sound understanding of the 
nature of barriers to research and for solutions to be gener-
ated and shared.
Our objective to explore what could be learnt from cur-
rent research regarding recruitment practices was limited by 
a lack of reporting. Such learning is important to enhance 
success of future projects, thereby reducing waste and unnec-
essary exposure of CYP to suboptimal practices. Inadequate 
reporting of recruitment practices limits our capacity to judge 
study quality, risk of bias, representativeness of samples, 
generalizability of results and ultimately the applicability of 
findings. This has worrying implications for the policies 
which are underpinned by the current evidence base.
Strengths and limitations
The lack of reporting about recruitment processes meant 
that while we were able to conduct a narrative synthesis of 
the data, and a thematic synthesis of text from the discus-
sion section of included papers provided, it was not possi-
ble to conduct an analysis of the association between 
research aim, recruitment strategies and recruitment rates.
We recognize that one potential explanation for the lack 
of information about recruitment processes may be related 
to journal constraints and word limits. In addition, for 
some variables, such as reasons for non-participation, 
researchers may not have access to this information, or 
may not have had the ethical approvals to collect and 
record data on non-participation. Nonetheless, the rate of 
recruitment reporting is lower than we had anticipated.
Our review was limited to studies published in English 
over the last 5 years, which may have introduced the poten-
tial for a language or publishing bias; however, studies 
from a range of countries were included. We restricted our-
selves to the last 5 years for both practical reasons (limited 
resources) and in order to focus on the most current report-
ing practices. We did not include studies with mixed popu-
lations (studies recruiting CYP with LLC/LTI plus healthy 
controls or professionals involved in their care). Given the 
uniqueness of this population, we wanted to focus exclu-
sively on CYP with LLC/LTI and their families. We are 
unable to comment on the reporting of recruitment prac-
tices in studies recruiting more heterogeneous populations.
The inclusion and analysis of informal data in systematic 
reviews are not common but have been successfully imple-
mented in a few pioneering studies.27,41 Informal evidence 
provided a richer, fuller picture of recruitment than formal 
evidence alone. However, as relevant text was extracted 
from just over a quarter of reviewed studies (26%), the 
potential for biases within the data reviewed exists.
A potential criticism of this review could be the group-
ing of both medical (e.g. drug trials) and psychosocial 
studies under the research aim ‘evaluating an interven-
tion’. We acknowledge that requirements and methodolo-
gies of studies within this category vary, yet these are the 
only studies for which there is the potential for direct phys-
ical participant benefit. The majority of studies within this 
category evaluated a medical intervention and from the 
data reported, there appears to be minimal differences 
between research with different aims in terms of recruit-
ment methodologies used and recruitment rates achieved.
Recommendations for reporting of recruitment
In order to strengthen the evidence base and inform the 
development of future research and policies to improve the 
care and treatment of CYP with LLC/LTI and their fami-
lies, greater clarity is needed in the reporting of research 
conducted with this population.
Future research should endeavour to provide transpar-
ent accounts of participant recruitment. In order to achieve 
this goal, we would urge authors to report recruitment 
methods and practices and we would encourage journals to 
make this part of the manuscript submission requirements. 
The use of online supplementary material facilities should 
be used where authors are constrained by word limits.
Implications for future research
Based on the content of recently published papers, we can-
not judge the impact of different recruitment strategies or 
the extent of impact of the barriers reported due to the 
inadequacies of current reporting practices. Explorations 
of the effectiveness of different identification, invitation 
and recruitment strategies and the impact of flexibility in 
recruitment may serve to strengthen the evidence base and 
advance the care and treatment of CYP with LLC/LTI and 
their families. Further reviews of existing literature, 
including studies with mixed populations (those recruiting 
CYP with LLC/LTI plus healthy controls or professionals 
involved in their care), could prove illuminating.
This review has pooled the experiences of researchers’ 
recruiting CYP with LLC/LTI and their families to research 
in an attempt to explore recruitment practices employed, 
barriers encountered and steps taken to overcome them. 
Expanding this approach and further drawing upon both 
researchers’ and participants’ experiences and expertise 
could enable solutions to be generated, developed, imple-
mented and shared among the research community. 
Researchers’ recommendations for facilitating the recruit-
ment of this population spoke to the importance of listen-
ing to the views and preferences of potential participants 
with regard to research participation, and accommodating 
these preferences where possible.
We cannot presume to know what constitutes an unac-
ceptable burden to research participation from the perspec-
tive of CYP with LLC/LTI and/or their families. Providing 
 at University College London on September 12, 2016pmj.sagepub.comDownloaded from 
10 Palliative Medicine 
consenting participants, in research of all designs, with the 
opportunity to share their reasons for deciding to partici-
pate, and their views on what constitutes a burden or bar-
rier to research could provide meaningful and useful 
insights into the research experience of this population and 
could inform the development of future research design 
and recruitment.
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Appendix 1
MEDLINE search terms
1. Children and young people
Neonate* or newborn or new born or infant* or child* or 
adolescen* or pediatric or paediatric* or baby or babies or 
toddler* or juvenile* or boy* or girl* OR ‘child’ [MeSH 
Terms]) OR ‘infant’ [MeSH Terms]) OR ‘adolescent’ 
[MeSH Terms]) OR ‘pediatrics’ [MeSH Terms].
2. Life-limiting conditions and life-threatening 
illnesses
palliative) OR life threatening) OR life limiting) OR end 
of life) OR terminal care) OR terminal illness) OR 
bereave*) OR death) OR dying) OR ‘palliative care’ 
[MeSH Terms]) OR ‘terminally ill’ [MeSH Terms]) OR 
‘death’ [MeSH Terms]) OR ‘terminal care’ [MeSH Terms]) 
OR ‘bereavement’ [MeSH Terms].
3. Invitation and recruitment practices
(participat* or recruit* or enrol* or invit* or select* or atti-
tude* to research or accrual or enlist* or non-participat*)) 
OR (‘patient selection’ [MeSH Terms] OR ‘patient partici-
pation’ [MeSH Terms] OR ‘research subjects’ [MeSH 
Terms] OR ‘researcher-subject relations’ [MeSH Terms] 
OR ‘refusal to participate’ [MeSH])))))).
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